SCHEDULE: Vanguard Group Reports Zero Stake in Fulcrum Therapeutics

The Vanguard Group has reported a 0% beneficial ownership in Fulcrum Therapeutics Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 2 to Schedule 13G for Fulcrum Therapeutics Inc.
• As of March 13, 2026, The Vanguard Group beneficially owns 0 shares of Fulcrum Therapeutics Inc. Common Stock, representing 0% of the class.
• This change is attributed to an internal realignment within The Vanguard Group that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, procedural filing reflecting an internal organizational change at Vanguard rather than a direct investment decision regarding Fulcrum Therapeutics. It does not inherently convey positive or negative sentiment about the issuer.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Fulcrum Therapeutics Inc.'s operations or financial performance, focusing solely on The Vanguard Group's beneficial ownership change.

Management Comments

• The Vanguard Group, Inc. underwent an internal realignment on January 12, 2026.
• Certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately, in reliance on SEC Release No. 34-39538.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that institutional ownership changes, particularly from major asset managers like Vanguard, are closely monitored by the market. A reduction to 0% by the parent entity, even if due to internal restructuring and disaggregated reporting, can sometimes lead to misinterpretations if the underlying holdings by its subsidiaries are not clearly understood.

Stakeholder Impact

• Shareholders of Fulcrum Therapeutics Inc. might observe a change in the reported beneficial ownership by The Vanguard Group, though the underlying investment by Vanguard's broader organization may remain consistent through its subsidiaries.

Next Steps

• Certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately in future filings.

Key Dates

Keywords

Fulcrum Therapeutics, Vanguard Group, Schedule 13G, beneficial ownership, institutional ownership, common stock, investment adviser